Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Business
Cephalon Will Buy Generics Firm Mepha
by Lisa M. Jarvis
February 8, 2010
| A version of this story appeared in
Volume 88, Issue 6
In a bid to diversify its product offerings, Cephalon will pay roughly $590 million for the Swiss generic drug firm Mepha. Privately held Mepha’s 120 products are marketed in 50 countries and brought in sales of $377 million in 2009. The company has 50 more drugs scheduled for launch by 2015. The deal underscores the pressure on drug companies to find new markets. Although major drugmakers have been pushing into generics and emerging markets in hopes of serving new customers, Cephalon is one of the first biotech firms to make such a move.
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter